多种炎症指标对冠心病患者PCI术后冠脉病变进展的预测价值

摘要/Abstract

摘要： 目的分析系统性炎症反应指数SIRI、泛免疫炎症值PIV、预后营养指数PNI等多种炎症指标对于冠心病患者经皮冠状动脉介入治疗（PCI）术后冠脉靶病变与非靶病变进展的预测价值。方法选取2019年1月至2023年12月于安徽医科大学第二附属医院接受PCI治疗且在术后6-24个月复查冠状动脉造影的213例冠心病患者,根据冠脉病变是否进展分为未进展组、非靶病变进展组及靶病变进展组,评估多种炎症指标对于冠脉病变进展的预测价值。结果两个进展组SIRI[非靶病变进展组1.71（0.91-2.95） vs 靶病变进展组1.23（0.88-1.89） vs 未进展组0.91（0.69-1.38）]、PIV[非靶病变进展组348.75（184.60-630.58） vs 靶病变进展组207.15（138.66-353.19） vs 未进展组177.10（125.73-298.21）]等多种炎症指标均较高,PNI[非靶病变进展组47.10（42.35-51.04） vs 靶病变进展组46.20（43.70-48.86） vs 未进展组48.60（47.00-51.20）]均较低,差异有统计学意义（P<0.05）。多因素Logistic回归显示,SIRI、PNI是冠脉病变进展独立影响因素（P<0.05）。绘制受试者工作（ROC）曲线提示,SIRI、PIV、PNI以及三者联合对于冠心病患者PCI术后冠脉靶病变进展及非靶病变进展均有预测价值（P<0.05）。结论冠心病患者PCI术后冠脉病变的进展受多种炎症指标的影响,其中SIRI、PIV、PNI联合检验对于冠脉非靶病变进展及靶病变进展有着较高的预测价值。

关键词: 系统性炎症反应指数, 泛免疫炎症值, 预后营养指数, 冠心病, 经皮冠状动脉介入治疗

麻昌伟, 盛建龙. 多种炎症指标对冠心病患者PCI术后冠脉病变进展的预测价值[J]. 心血管病防治知识, 2026, 16(10): 60-66.

参考文献

[1] 中国心血管健康与疾病报告2023概要[J].中国循环杂志,2024,39(7):625-660.
[2] Edwards NC, Ferro CJ, Townend JN.Heart disease and stroke statistics 2023 update from the American Heart Association-implications for nephrology[J]. Nephrol Dial Transplant, 2024,39(3):387-394.
[3] Dasaro C, Mandrola J, Murthy V, et al.The History of Angina and Its Remedies: , , and a Path Forward[J]. Cardiol Rev, 2025.
[4] Ralapanawa U, Sivakanesan R.Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review[J]. J Epidemiol Glob Health, 2021, 11(2): 169-177.
[5] Räber L, Ueki Y, Otsuka T, et al.Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The-AMI Randomized Clinical Trial[J]. JAMA,2022, 327(18): 1771-1781.
[6] Kuramitsu S, Sonoda S, Ando K, et al.Drug-eluting stent thrombosis: current and future perspectives[J]. Cardiovasc Interv Ther, 2021, 36(2): 158-168.
[7] McPherson R, Davies RW. Inflammation and coronary artery disease: insights from genetic studies[J]. Can J Cardiol, 2012, 28(6): 662-666.
[8] Knuuti J, Wijns W, Saraste A, et al.2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes[J]. Eur Heart J, 2020, 41(3): 407-477.
[9] Dziedzic EA, Gąsior JS, Tuzimek A, et al.Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index ()-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence[J]. Int J Mol Sci, 2022, 23(17): 9553.
[10] Zhao Z, Lian H, Liu Y, et al.Application of systemic inflammation indices and lipid metabolism-related factors in coronary artery disease[J]. Coron Artery Dis, 2023, 34(5): 306-313.
[11] 江文韬,郑志敏.老年营养风险指数联合炎症因子和心功能标志物预测急性非ST段抬高型心肌梗死患者PCI术后发生不良心血管事件的价值[J].心血管病防治知识,2025,15(18):26-29.
[12] Qu C, Li X, Gao H.The Impact of Systemic Inflammation Response Index on the Prognosis of Patients with ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention[J]. Rev Cardiovasc Med, 2023, 24(5): 153.
[13] Piraino D, Cimino G, Buccheri D, et al.Recurrent in-stent restenosis, certainty of its origin, uncertainty about treatment[J]. Int J Cardiol, 2017, 230: 91-96.
[14] 武怿臻,杨光.美托洛尔与曲美他嗪联合治疗冠心病稳定型心绞痛的有效性及对血清炎症因子的影响[J].心血管病防治知识,2024,14(16):6-9.
[15] Libby P.Inflammation and the pathogenesis of atherosclerosis[J]. Vascul Pharmacol, 2024, 154: 107255.
[16] 兰江,何国强,陈明慧.SII联合血清cTnI对冠心病伴心力衰竭患者主要不良心血管事件的预测价值[J].心血管病防治知识,2025,15(11):18-21.
[17] Arques S.Human serum albumin in cardiovascular diseases[J]. Eur J Intern Med, 2018, 52: 8-12.
[18] Cetinkaya Z, Kelesoglu S, Tuncay A, Yilmaz Y, Karaca Y, Karasu M, Secen O, Cinar A, Harman M, Sahin S, Akin Y, Yavcin O.The Role of Pan-Immune-Inflammation Value in Determining the Severity of Coronary Artery Disease in Patients[J]. J Clin Med, 2024, 13(5): 1295.
[19] Davis FM, Gallagher KA.Epigenetic Mechanisms in Monocytes/Macrophages Regulate Inflammation in Cardiometabolic and Vascular Disease[J]. Arterioscler Thromb Vasc Biol, 2019, 39(4): 623-634.
[20] 潘颖,郑颖颖,吴婷婷,等.基线外周血循环单核细胞水平对冠心病患者经皮冠状动脉介入治疗后长期死亡风险的影响[J].中国动脉硬化杂志,2021,29(12):1059-1065.